Skip to main content
NCBI home page
CMAJ : Canadian Medical Association Journal logoLink to CMAJ : Canadian Medical Association Journal
. 1996 Oct 1;155(7):955–961.

Prevention and management of osteoporosis: consensus statements from the Scientific Advisory Board of the Osteoporosis Society of Canada. 8. Vitamin D metabolites and analogs in the treatment of osteoporosis.

G Jones 1, D B Hogan 1, E Yendt 1, D A Hanley 1
PMCID: PMC1335461  PMID: 8837546

Abstract

OBJECTIVE: To review recent findings on the skeletal actions of vitamin D and to examine results of the latest clinical trials of vitamin D in the treatment of osteoporosis. OPTIONS: The vitamin D analog 1-alpha hydroxycholecalciferol (1 alpha-OH-D3); the vitamin D metabolite calcitriol. OUTCOMES: Fracture and loss of bone mineral density in osteoporosis; increased bone mass, prevention of fractures and improved quality of life associated with vitamin D therapies. EVIDENCE: Relevant laboratory and clinical studies and reports were examined. Greatest reliance was placed on recent large-scale, randomized, controlled trials; others were noted and their methods critiqued. Clinical practice in Japan was also considered. VALUES: Reducing fractures, increasing bone mineral density and minimizing side effects of treatment were given a high value. BENEFITS, HARMS AND COSTS: Vitamin D maintains the dynamic nature of bone and so presumably helps to keep it healthy. Calcitriol and 1 alpha-OH-D3 may be effective in increasing bone mass and preventing fractures in osteoporosis. Calcitriol may be an alternative treatment in the prevention and management of corticosteroid-induced osteoporosis. Possible side effects of vitamin D analogs and metabolites are hypercalcemia, hypercalciuria, renal calcification and renal stones. RECOMMENDATIONS: The use of 1 alpha-OH-D3 for the treatment of osteoporosis in Canada cannot be supported without larger and longer randomized, controlled clinical trials. Calcitriol appears to prevent vertebral fractures in patients with osteoporosis. More information is needed on its mechanism of action and efficacy in preventing hip fractures. Future studies should focus on comparisons with other effective therapies and on determining whether its effect on fractures is greater than that achieved through improved vitamin D nutrition. Patients taking calcitriol at dose levels required for antifracture effects should be monitored for serum and urine calcium response to the drug. Calcitriol should not be given to patients whose calcium intake is at current generally recommended levels. At present, prescription of calcitriol for the treatment of osteoporosis should be reserved for physicians with a special interest in the treatment of metabolic bone disease.

Full text

PDF
955

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abe E., Miyaura C., Sakagami H., Takeda M., Konno K., Yamazaki T., Yoshiki S., Suda T. Differentiation of mouse myeloid leukemia cells induced by 1 alpha,25-dihydroxyvitamin D3. Proc Natl Acad Sci U S A. 1981 Aug;78(8):4990–4994. doi: 10.1073/pnas.78.8.4990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Abe E., Miyaura C., Tanaka H., Shiina Y., Kuribayashi T., Suda S., Nishii Y., DeLuca H. F., Suda T. 1 alpha,25-dihydroxyvitamin D3 promotes fusion of mouse alveolar macrophages both by a direct mechanism and by a spleen cell-mediated indirect mechanism. Proc Natl Acad Sci U S A. 1983 Sep;80(18):5583–5587. doi: 10.1073/pnas.80.18.5583. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Aloia J. F., Vaswani A., Yeh J. K., Ellis K., Yasumura S., Cohn S. H. Calcitriol in the treatment of postmenopausal osteoporosis. Am J Med. 1988 Mar;84(3 Pt 1):401–408. doi: 10.1016/0002-9343(88)90259-8. [DOI] [PubMed] [Google Scholar]
  4. Bar-Shavit Z., Teitelbaum S. L., Reitsma P., Hall A., Pegg L. E., Trial J., Kahn A. J. Induction of monocytic differentiation and bone resorption by 1,25-dihydroxyvitamin D3. Proc Natl Acad Sci U S A. 1983 Oct;80(19):5907–5911. doi: 10.1073/pnas.80.19.5907. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Bhalla A. K., Amento E. P., Clemens T. L., Holick M. F., Krane S. M. Specific high-affinity receptors for 1,25-dihydroxyvitamin D3 in human peripheral blood mononuclear cells: presence in monocytes and induction in T lymphocytes following activation. J Clin Endocrinol Metab. 1983 Dec;57(6):1308–1310. doi: 10.1210/jcem-57-6-1308. [DOI] [PubMed] [Google Scholar]
  6. Bikle D. D. Role of vitamin D, its metabolites, and analogs in the management of osteoporosis. Rheum Dis Clin North Am. 1994 Aug;20(3):759–775. [PubMed] [Google Scholar]
  7. Blunt J. W., DeLuca H. F., Schnoes H. K. 25-hydroxycholecalciferol. A biologically active metabolite of vitamin D3. Biochemistry. 1968 Oct;7(10):3317–3322. doi: 10.1021/bi00850a001. [DOI] [PubMed] [Google Scholar]
  8. Bouillon R., Okamura W. H., Norman A. W. Structure-function relationships in the vitamin D endocrine system. Endocr Rev. 1995 Apr;16(2):200–257. doi: 10.1210/edrv-16-2-200. [DOI] [PubMed] [Google Scholar]
  9. Chang P. L., Prince C. W. 1 alpha,25-Dihydroxyvitamin D3 enhances 12-O-tetradecanoylphorbol-13-acetate- induced tumorigenic transformation and osteopontin expression in mouse JB6 epidermal cells. Cancer Res. 1993 May 15;53(10 Suppl):2217–2220. [PubMed] [Google Scholar]
  10. Chapuy M. C., Arlot M. E., Duboeuf F., Brun J., Crouzet B., Arnaud S., Delmas P. D., Meunier P. J. Vitamin D3 and calcium to prevent hip fractures in the elderly women. N Engl J Med. 1992 Dec 3;327(23):1637–1642. doi: 10.1056/NEJM199212033272305. [DOI] [PubMed] [Google Scholar]
  11. DeLuca H. F. The metabolism and functions of vitamin D. Adv Exp Med Biol. 1986;196:361–375. doi: 10.1007/978-1-4684-5101-6_24. [DOI] [PubMed] [Google Scholar]
  12. DeLuca H. F. The vitamin D story: a collaborative effort of basic science and clinical medicine. FASEB J. 1988 Mar 1;2(3):224–236. [PubMed] [Google Scholar]
  13. Fraser D. R., Kodicek E. Unique biosynthesis by kidney of a biological active vitamin D metabolite. Nature. 1970 Nov 21;228(5273):764–766. doi: 10.1038/228764a0. [DOI] [PubMed] [Google Scholar]
  14. Fraser J. D., Price P. A. Induction of matrix Gla protein synthesis during prolonged 1,25-dihydroxyvitamin D3 treatment of osteosarcoma cells. Calcif Tissue Int. 1990 Apr;46(4):270–279. doi: 10.1007/BF02555007. [DOI] [PubMed] [Google Scholar]
  15. Fujita T. Studies of osteoporosis in Japan. Metabolism. 1990 Apr;39(4 Suppl 1):39–42. doi: 10.1016/0026-0495(90)90271-d. [DOI] [PubMed] [Google Scholar]
  16. Gallagher J. C., Goldgar D. Treatment of postmenopausal osteoporosis with high doses of synthetic calcitriol. A randomized controlled study. Ann Intern Med. 1990 Nov 1;113(9):649–655. doi: 10.7326/0003-4819-113-9-649. [DOI] [PubMed] [Google Scholar]
  17. Gallagher J. C., Riggs B. L., Recker R. R., Goldgar D. The effect of calcitriol on patients with postmenopausal osteoporosis with special reference to fracture frequency. Proc Soc Exp Biol Med. 1989 Jul;191(3):287–292. doi: 10.3181/00379727-191-42922. [DOI] [PubMed] [Google Scholar]
  18. Girasole G., Passeri G., Jilka R. L., Manolagas S. C. Interleukin-11: a new cytokine critical for osteoclast development. J Clin Invest. 1994 Apr;93(4):1516–1524. doi: 10.1172/JCI117130. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Haussler M. R. Vitamin D receptors: nature and function. Annu Rev Nutr. 1986;6:527–562. doi: 10.1146/annurev.nu.06.070186.002523. [DOI] [PubMed] [Google Scholar]
  20. Kim H. T., Chen T. L. 1,25-Dihydroxyvitamin D3 interaction with dexamethasone and retinoic acid: effects on procollagen messenger ribonucleic acid levels in rat osteoblast-like cells. Mol Endocrinol. 1989 Jan;3(1):97–104. doi: 10.1210/mend-3-1-97. [DOI] [PubMed] [Google Scholar]
  21. Lin H. Y., Harris T. L., Flannery M. S., Aruffo A., Kaji E. H., Gorn A., Kolakowski L. F., Jr, Lodish H. F., Goldring S. R. Expression cloning of an adenylate cyclase-coupled calcitonin receptor. Science. 1991 Nov 15;254(5034):1022–1024. doi: 10.1126/science.1658940. [DOI] [PubMed] [Google Scholar]
  22. Mahonen A., Pirskanen A., Keinänen R., Mäenpä P. H. Effect of 1,25(OH)2D3 on its receptor mRNA levels and osteocalcin synthesis in human osteosarcoma cells. Biochim Biophys Acta. 1990 Jan 30;1048(1):30–37. doi: 10.1016/0167-4781(90)90018-w. [DOI] [PubMed] [Google Scholar]
  23. Manolagas S. C., Jilka R. L. Bone marrow, cytokines, and bone remodeling. Emerging insights into the pathophysiology of osteoporosis. N Engl J Med. 1995 Feb 2;332(5):305–311. doi: 10.1056/NEJM199502023320506. [DOI] [PubMed] [Google Scholar]
  24. Merke J., Klaus G., Hügel U., Waldherr R., Ritz E. No 1,25-dihydroxyvitamin D3 receptors on osteoclasts of calcium-deficient chicken despite demonstrable receptors on circulating monocytes. J Clin Invest. 1986 Jan;77(1):312–314. doi: 10.1172/JCI112292. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Morrison N. A., Qi J. C., Tokita A., Kelly P. J., Crofts L., Nguyen T. V., Sambrook P. N., Eisman J. A. Prediction of bone density from vitamin D receptor alleles. Nature. 1994 Jan 20;367(6460):284–287. doi: 10.1038/367284a0. [DOI] [PubMed] [Google Scholar]
  26. Orimo H., Shiraki M., Hayashi T., Nakamura T. Reduced occurrence of vertebral crush fractures in senile osteoporosis treated with 1 alpha (OH)-vitamin D3. Bone Miner. 1987 Oct;3(1):47–52. [PubMed] [Google Scholar]
  27. Ott S. M., Chesnut C. H., 3rd Calcitriol treatment is not effective in postmenopausal osteoporosis. Ann Intern Med. 1989 Feb 15;110(4):267–274. doi: 10.7326/0003-4819-110-4-267. [DOI] [PubMed] [Google Scholar]
  28. Pike J. W. Vitamin D3 receptors: structure and function in transcription. Annu Rev Nutr. 1991;11:189–216. doi: 10.1146/annurev.nu.11.070191.001201. [DOI] [PubMed] [Google Scholar]
  29. Ross P. D., Davis J. W., Epstein R. S., Wasnich R. D. Pre-existing fractures and bone mass predict vertebral fracture incidence in women. Ann Intern Med. 1991 Jun 1;114(11):919–923. doi: 10.7326/0003-4819-114-11-919. [DOI] [PubMed] [Google Scholar]
  30. Sambrook P., Birmingham J., Kelly P., Kempler S., Nguyen T., Pocock N., Eisman J. Prevention of corticosteroid osteoporosis. A comparison of calcium, calcitriol, and calcitonin. N Engl J Med. 1993 Jun 17;328(24):1747–1752. doi: 10.1056/NEJM199306173282404. [DOI] [PubMed] [Google Scholar]
  31. Shiraki M., Ito H., Orimo H. The ultra long-term treatment of senile osteoporosis with 1 alpha-hydroxyvitamin D3. Bone Miner. 1993 Mar;20(3):223–234. doi: 10.1016/s0169-6009(08)80003-7. [DOI] [PubMed] [Google Scholar]
  32. Suda T., Takahashi N., Abe E. Role of vitamin D in bone resorption. J Cell Biochem. 1992 May;49(1):53–58. doi: 10.1002/jcb.240490110. [DOI] [PubMed] [Google Scholar]
  33. Tilyard M. W., Spears G. F., Thomson J., Dovey S. Treatment of postmenopausal osteoporosis with calcitriol or calcium. N Engl J Med. 1992 Feb 6;326(6):357–362. doi: 10.1056/NEJM199202063260601. [DOI] [PubMed] [Google Scholar]
  34. Tsoukas C. D., Provvedini D. M., Manolagas S. C. 1,25-dihydroxyvitamin D3: a novel immunoregulatory hormone. Science. 1984 Jun 29;224(4656):1438–1440. doi: 10.1126/science.6427926. [DOI] [PubMed] [Google Scholar]
  35. Watson P. H., Hanley D. A. Parathyroid hormone: regulation of synthesis and secretion. Clin Invest Med. 1993 Feb;16(1):58–77. [PubMed] [Google Scholar]
  36. Zaidi M., Pazianas M., Shankar V. S., Bax B. E., Bax C. M., Bevis P. J., Stevens C., Huang C. L., Blake D. R., Moonga B. S. Osteoclast function and its control. Exp Physiol. 1993 Nov;78(6):721–739. doi: 10.1113/expphysiol.1993.sp003721. [DOI] [PubMed] [Google Scholar]

Articles from CMAJ: Canadian Medical Association Journal are provided here courtesy of Canadian Medical Association

RESOURCES